RxDoctor Payments Data

Mary Melissa McBrien, MD

Otolaryngology · West Bloomfield, MINPI 1861474009

Payments from drug & device makers

$2,116in general payments, 2019–2025

Across 38 payments — averaging $55.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intersect ENT, Inc.$547
  • Medtronic$363
  • Stryker$311
  • Acclarent, Inc$284
  • Optinose US, Inc.$248
  • Inspire Medical Systems, Inc.$160
  • plus $203 from 8 others

What the payments were for

  • Food & beverage$2,116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,116 in reported general payments places this provider in the 60th percentile of 257 otolaryngology providers in Michigan.

See all otolaryngology providers in Michigan

Medicare billing

Part B allowed, 2024
$90,566
Medicare patients
414
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate20$12,264
Ipratropium Bromide110$4,303
Montelukast Sodium139$1,921
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip22$1,902
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth14$1,529
Famotidine103$1,282
Azelastine Hcl14$323
Triamcinolone Acetonide12$281
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav30$262
Mometasone Furoate11$243
Pantoprazole Sodium12$243
Levocetirizine Dihydrochloride26$203
Fluocinolone Acetonide11$140
Mupirocin32$125
Fluconazole14$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$248$12,26420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 257 otolaryngology providers in Michigan.

Other otolaryngology in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →